This study was funded by National Key R&D Program of China(2017YFC1308200);Stroke Prevention and Treatment Project of the National Health Commission-Research and Popularization of Appropriate Intervention Technology for the Stroke High Risk Group in China(GN-2016R0008).
Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being availabl...
Objective: To reveal the factors leading to delay in the evaluation processes of patients with suspected acute ischemic stroke at Yozgat City Hospital in Turkey and suggest potential solutions. Methods: Patients who v...
Funded by Key Discipline Group Construction Project of Pudong Health Bureau of Shanghai(Grant No.PWZxq2017-02);by The Featured Clinical Discipline Project of Shanghai Pudong(Grant No.PWYst2018-01).
Purpose Clinical trials have provided evidence that treating patients with acute ischaemic stroke(AIS)beyond 4.5 hours was feasible.Among them using MRI diffusion-weighted imaging/fluid attenuation inversion response(...
At present, the only FDA approved treatment for ischemic strokes is intravenous administration of tissue plasminogen activator within 4.5 hours of stroke onset. Owing to this brief window only a small percentage of pa...